These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 33072593)
1. Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report. Ikarashi D; Kitano S; Ishida K; Nakatsura T; Shimodate H; Tsuyukubo T; Tamura D; Kato R; Sugai T; Obara W Front Oncol; 2020; 10():564714. PubMed ID: 33072593 [TBL] [Abstract][Full Text] [Related]
2. Positive voided urine cytology predicts worse pathological findings of nephroureterectomy specimens in patients with upper tract urothelial carcinoma: does selective ureteral cytology have an additional efficacy? Sakano S; Inamoto T; Inoue R; Matsumoto H; Nagao K; Yamamoto Y; Azuma H; Matsuyama H Jpn J Clin Oncol; 2015 Oct; 45(10):968-72. PubMed ID: 26232447 [TBL] [Abstract][Full Text] [Related]
3. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485 [TBL] [Abstract][Full Text] [Related]
4. Urothelial carcinoma of the bladder and the upper tract: disparate twins. Green DA; Rink M; Xylinas E; Matin SF; Stenzl A; Roupret M; Karakiewicz PI; Scherr DS; Shariat SF J Urol; 2013 Apr; 189(4):1214-21. PubMed ID: 23023150 [TBL] [Abstract][Full Text] [Related]
5. Complete remission following pembrolizumab therapy for a patient with nephroureterectomy positive-margin carcinoma in situ and bladder cancer unresponsive to Bacille Calmette-Guérin therapy. Nakamura R; Hasegawa G; Ikeda Y; Hara N; Nishiyama T SAGE Open Med Case Rep; 2023; 11():2050313X231185444. PubMed ID: 37440976 [TBL] [Abstract][Full Text] [Related]
6. Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report. Ding X; Zong J; Li X; Bai X; Tan B; Sun W; Wang R; Ding Y Onco Targets Ther; 2021; 14():2177-2183. PubMed ID: 33790580 [TBL] [Abstract][Full Text] [Related]
7. Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report. Hasegawa M; Hasegawa G; Ikeda Y; Hara N; Nishiyama T SAGE Open Med Case Rep; 2020; 8():2050313X20932694. PubMed ID: 32587697 [TBL] [Abstract][Full Text] [Related]
8. Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy. Kawahara T; Mochizuki T; Sugimura R; Izumi K; Kuroda S; Miyoshi Y; Nakaigawa N; Yao M; Tanabe M; Uemura H Case Rep Oncol; 2019; 12(2):548-553. PubMed ID: 31427950 [TBL] [Abstract][Full Text] [Related]
9. Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure. Zan N; Zhang X; Du L; Lin Z; Yu D; Liu J; Gou F Front Oncol; 2022; 12():796407. PubMed ID: 35296012 [TBL] [Abstract][Full Text] [Related]
10. A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report. Wang J; Li Q; Lv H; Nie C; Chen B; Xu W; Yang T; Zhang Y; Tu S; Chen X Front Oncol; 2021; 11():671416. PubMed ID: 34221988 [TBL] [Abstract][Full Text] [Related]
11. First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report. Hunter L; Moser J; Sturge C; Barraza G; Colonna S J Oncol Pharm Pract; 2020 Jan; 26(1):216-219. PubMed ID: 30832555 [TBL] [Abstract][Full Text] [Related]
12. [ONE COURSE OF PEMBROLIZUMAB AFTER RADIATION THERAPY WAS VERY EFFECTIVE AGAINST METASTATIC BLADDER CANCER AND CR WAS CONFIRMED: A CASE REPORT]. Sakamoto T; Fujimoto N; Nakashima M Nihon Hinyokika Gakkai Zasshi; 2021; 112(4):220-223. PubMed ID: 36261353 [TBL] [Abstract][Full Text] [Related]
13. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report. Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433 [TBL] [Abstract][Full Text] [Related]
14. Successful treatment of metastatic bladder cancer by gemcitabine-cisplatin re-challenge after pembrolizumab. Arai T; Takeuchi N; Sazuka T; Sato H; Imamura Y; Sakamoto S; Komiya A; Ichikawa T IJU Case Rep; 2021 Nov; 4(6):360-362. PubMed ID: 34755056 [TBL] [Abstract][Full Text] [Related]
15. Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma. Fukuta K; Izaki H; Shiozaki K; Nakanishi R; Inai T; Kataoka H; Kudo E; Kanda K IJU Case Rep; 2021 Sep; 4(5):310-313. PubMed ID: 34497992 [TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754 [TBL] [Abstract][Full Text] [Related]